BioPharmSignal logoBioPharmSignal

Biotech News

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Earnings

MONTREAL and CHARLOTTE, May 06, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the first quarter

Open original release

Related news

MISTMilestone Pharmaceuticals Inc.2026-03-12 12:00 EST

Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MLYSMineralys Therapeutics2026-04-29 20:05 EST

Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

ALGSAligos Therapeutics2026-04-30 20:05 EST

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

MNKDMannKind2026-04-29 20:01 EST

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

CVRXCVRx2026-04-27 20:30 EST

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

MLYSMineralys Therapeutics2026-03-09 12:00 EST

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

ALGSAligos Therapeutics2026-02-26 13:00 EST

Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

NAMSNewAmsterdam Pharma2026-05-07 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

View all latest news

Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals is a specialty pharmaceutical company focused on cardiovascular and episodic-care therapies, with a strong emphasis on acute treatment use cases. Its business is built around fast-acting symptom management rather than chronic broad-market therapeutics.

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-05-06 12:00 EST

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

MISTMilestone Pharmaceuticals Inc.2026-04-10 12:00 EST

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT

MISTMilestone Pharmaceuticals Inc.2026-04-07 12:30 EST

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

Stock data

Close
1.13 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States